Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05429021 · ClinicalTrials.gov registry record · Phase 1
IMM-BCP-01 in Mild to Moderate COVID-19
A Phase 1 study, sponsored by Immunome.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT05429021: Clinical Trial Phase 1 study, sponsored by Immunome.
NCT05429021 is a Phase 1 study that was terminated before completion, run by Immunome. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05429021, a Phase 1 study, was terminated before completion, sponsored by Immunome.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and tolerability of intravenous (IV) IMM-BCP-01 in subjects with mild to moderate COVID-19 through Day 28. The secondary objectives of the study are to: * Determine pharmacokinetics (PK) and evaluate viral clearance after single ascending doses of IV IMM-BCP-01 in subjects with mild to moderate COVID-19 through Day 28. * Evaluate the safety and tolerability, determine PK, and evaluate viral clearance of single ascending doses of IV IMM-BCP-01 in subjects with mild to moderate COVID-19 through Week 12.
Primary Outcome
TEAEs include clinical laboratory values, standard 12-lead ECGs, vital signs, pulse oximetry
Interventions
- DRUG Placebo
- DRUG IMM-BCP-01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2022-06-03 |
| Est. Completion | 2023-01-06 |
| Phase | Phase 1 |
Why NCT05429021 stopped before completion
NCT05429021 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05429021 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05429021 about?
NCT05429021 is a clinical study titled "IMM-BCP-01 in Mild to Moderate COVID-19". The primary objective of this study is to evaluate the safety and tolerability of intravenous (IV) IMM-BCP-01 in subjects with mild to moderate COVID-19 through Day 28. The secondary objectives of the study are to: * Determine pharmacokinetics (PK) and evaluate viral clearance after single ascendi...
What is the current status of trial NCT05429021?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2022-06-03. Estimated completion is 2023-01-06.
What interventions are being tested in trial NCT05429021?
The interventions under investigation include: Placebo (DRUG), IMM-BCP-01 (DRUG).
Who is sponsoring clinical trial NCT05429021?
This trial is sponsored by Immunome, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05429021's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI